901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT StudyWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Gastroenterology|2015Cited by 26
825 Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA StudyWilliam Sandborn, Geert D’Haens, Scott D. Lee et al.|Gastroenterology|2015Cited by 16
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II StudyGeert D’Haens, William J. Sandborn, Dino Tarabar et al.|Inflammatory Bowel Diseases|2021Cited by 16
OP024 Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II studyGeert D’Haens, William J. Sandborn, Walter Reinisch et al.|Journal of Crohn s and Colitis|2018Cited by 6
800 – Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib As an Induction Therapy in Adults with Moderately-To-Severely Active Ulcerative Colitis: Data from the U-Achieve StudyWilliam J. Sandborn, Edward V. Loftus, Stefan Schreiber et al.|Gastroenterology|2019Cited by 4